Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients. Soleimani, A., Mobedi, Z., Al-E-Rasul, M., Sharifi, A., & Vardanjani, A. K. Journal of clinical and diagnostic research: JCDR, 11(3):OC09–OC12, March, 2017. doi abstract bibtex INTRODUCTION: Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. AIM: The aim of this study was to investigate the effects of HLA-DRB1 gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA. MATERIALS AND METHODS: In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later. RESULTS: The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p\textless0.05). Of the patients, 81.3% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found. CONCLUSION: RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.
@article{soleimani_effect_2017,
title = {Effect of {Anti}-{Cyclic} {Citrullinated} {Peptide} and {HLA}-{DRB1} {Subtypes} on {Clinical} {Disease} {Activity} {Index} in {Rheumatoid} {Arthritis} {Patients}},
volume = {11},
issn = {2249-782X},
doi = {10.7860/JCDR/2017/8567.9436},
abstract = {INTRODUCTION: Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5\%-1\% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease.
AIM: The aim of this study was to investigate the effects of HLA-DRB1 gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA.
MATERIALS AND METHODS: In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later.
RESULTS: The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p{\textless}0.05). Of the patients, 81.3\% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found.
CONCLUSION: RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.},
language = {eng},
number = {3},
journal = {Journal of clinical and diagnostic research: JCDR},
author = {Soleimani, Akbar and Mobedi, Zahra and Al-E-Rasul, Maryam and Sharifi, Abolghasem and Vardanjani, Abdolrahim Kazemi},
month = mar,
year = {2017},
pmid = {28511426},
pmcid = {PMC5427352},
keywords = {Human leukocyte antigen, Rheumatic diseases, Rheumatoid Factor},
pages = {OC09--OC12},
}
Downloads: 0
{"_id":"2RFcDL4roYB3oFfYq","bibbaseid":"soleimani-mobedi-alerasul-sharifi-vardanjani-effectofanticycliccitrullinatedpeptideandhladrb1subtypesonclinicaldiseaseactivityindexinrheumatoidarthritispatients-2017","author_short":["Soleimani, A.","Mobedi, Z.","Al-E-Rasul, M.","Sharifi, A.","Vardanjani, A. K."],"bibdata":{"bibtype":"article","type":"article","title":"Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients","volume":"11","issn":"2249-782X","doi":"10.7860/JCDR/2017/8567.9436","abstract":"INTRODUCTION: Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. AIM: The aim of this study was to investigate the effects of HLA-DRB1 gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA. MATERIALS AND METHODS: In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later. RESULTS: The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p\\textless0.05). Of the patients, 81.3% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found. CONCLUSION: RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.","language":"eng","number":"3","journal":"Journal of clinical and diagnostic research: JCDR","author":[{"propositions":[],"lastnames":["Soleimani"],"firstnames":["Akbar"],"suffixes":[]},{"propositions":[],"lastnames":["Mobedi"],"firstnames":["Zahra"],"suffixes":[]},{"propositions":[],"lastnames":["Al-E-Rasul"],"firstnames":["Maryam"],"suffixes":[]},{"propositions":[],"lastnames":["Sharifi"],"firstnames":["Abolghasem"],"suffixes":[]},{"propositions":[],"lastnames":["Vardanjani"],"firstnames":["Abdolrahim","Kazemi"],"suffixes":[]}],"month":"March","year":"2017","pmid":"28511426","pmcid":"PMC5427352","keywords":"Human leukocyte antigen, Rheumatic diseases, Rheumatoid Factor","pages":"OC09–OC12","bibtex":"@article{soleimani_effect_2017,\n\ttitle = {Effect of {Anti}-{Cyclic} {Citrullinated} {Peptide} and {HLA}-{DRB1} {Subtypes} on {Clinical} {Disease} {Activity} {Index} in {Rheumatoid} {Arthritis} {Patients}},\n\tvolume = {11},\n\tissn = {2249-782X},\n\tdoi = {10.7860/JCDR/2017/8567.9436},\n\tabstract = {INTRODUCTION: Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5\\%-1\\% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease.\nAIM: The aim of this study was to investigate the effects of HLA-DRB1 gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA.\nMATERIALS AND METHODS: In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later.\nRESULTS: The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p{\\textless}0.05). Of the patients, 81.3\\% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found.\nCONCLUSION: RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Journal of clinical and diagnostic research: JCDR},\n\tauthor = {Soleimani, Akbar and Mobedi, Zahra and Al-E-Rasul, Maryam and Sharifi, Abolghasem and Vardanjani, Abdolrahim Kazemi},\n\tmonth = mar,\n\tyear = {2017},\n\tpmid = {28511426},\n\tpmcid = {PMC5427352},\n\tkeywords = {Human leukocyte antigen, Rheumatic diseases, Rheumatoid Factor},\n\tpages = {OC09--OC12},\n}\n\n","author_short":["Soleimani, A.","Mobedi, Z.","Al-E-Rasul, M.","Sharifi, A.","Vardanjani, A. K."],"key":"soleimani_effect_2017","id":"soleimani_effect_2017","bibbaseid":"soleimani-mobedi-alerasul-sharifi-vardanjani-effectofanticycliccitrullinatedpeptideandhladrb1subtypesonclinicaldiseaseactivityindexinrheumatoidarthritispatients-2017","role":"author","urls":{},"keyword":["Human leukocyte antigen","Rheumatic diseases","Rheumatoid Factor"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/tplas","dataSources":["YLgywGcXWx96vKKaB"],"keywords":["human leukocyte antigen","rheumatic diseases","rheumatoid factor"],"search_terms":["effect","anti","cyclic","citrullinated","peptide","hla","drb1","subtypes","clinical","disease","activity","index","rheumatoid","arthritis","patients","soleimani","mobedi","al-e-rasul","sharifi","vardanjani"],"title":"Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients","year":2017}